Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Jan. 9, 2015, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $172.97 to $43,403,664.41.

Highlighted Stocks Traded by Insiders:

Exa (EXA) - FREE Research Report

Remondi Stephen A., who is CEO and President at Exa, sold 10,000 shares at $10.79 on Jan. 9, 2015. Following this transaction, the CEO and President owned 102,359 shares meaning that the stake was reduced by 8.9% with the 10,000-share transaction.

The shares most recently traded at $11.34, up $0.55, or 4.81% since the insider transaction. Historical insider transactions for Exa go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 56,000

The average volume for Exa has been 19,300 shares per day over the past 30 days. Exa has a market cap of $150.4 million and is part of the technology sector and computer software & services industry. Shares are down 7.17% year-to-date as of the close of trading on Friday.

Exa Corporation develops, sells, and supports simulation software and services for vehicle manufacturers. It offers PowerFLOW and a suite of related software products for simulating complex fluid flow problems, including aerodynamics, thermal management, aeroacoustics, or wind noise. Currently, there are 3 analysts who rate Exa a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXA - FREE

TheStreet Quant Ratings rates Exa as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Exa Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CVD Equipment (CVV) - FREE Research Report

Rosenbaum Leonard A, who is Pres, CEO, Chairman at CVD Equipment, sold 20,000 shares at $15.07 on Jan. 9, 2015. Following this transaction, the Pres, CEO, Chairman owned 817,870 shares meaning that the stake was reduced by 2.39% with the 20,000-share transaction.

The shares most recently traded at $15.33, up $0.26, or 1.72% since the insider transaction. Historical insider transactions for CVD Equipment go as follows:

  • 4-Week # shares sold: 11,429
  • 12-Week # shares sold: 25,429
  • 24-Week # shares sold: 32,990

The average volume for CVD Equipment has been 26,200 shares per day over the past 30 days. CVD Equipment has a market cap of $93.3 million and is part of the industrial goods sector and industrial industry. Shares are up 14.52% year-to-date as of the close of trading on Friday.

CVD Equipment Corporation designs, develops, and manufactures customized equipment and process solutions used to develop and manufacture solar, nano, and advanced electronic components, materials, and coatings for research and industrial applications in the United States and internationally. The company has a P/E ratio of 380.0. Currently, there is 1 analyst who rates CVD Equipment a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVV - FREE

TheStreet Quant Ratings rates CVD Equipment as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full CVD Equipment Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Acceleron Pharma (XLRN) - FREE Research Report

Knopf John L, who is CEO and President at Acceleron Pharma, sold 20,000 shares at $39.62 on Jan. 9, 2015. Following this transaction, the CEO and President owned 56,500 shares meaning that the stake was reduced by 26.14% with the 20,000-share transaction.

The shares most recently traded at $41.13, up $1.51, or 3.68% since the insider transaction. Historical insider transactions for Acceleron Pharma go as follows:

  • 4-Week # shares bought: 1.1 million
  • 4-Week # shares sold: 43,400
  • 12-Week # shares bought: 1.1 million
  • 12-Week # shares sold: 116,118
  • 24-Week # shares bought: 1.1 million
  • 24-Week # shares sold: 185,618

The average volume for Acceleron Pharma has been 311,500 shares per day over the past 30 days. Acceleron Pharma has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 5.6% year-to-date as of the close of trading on Friday.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company has a P/E ratio of 29.2. Currently, there are 3 analysts who rate Acceleron Pharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XLRN - FREE

TheStreet Quant Ratings rates Acceleron Pharma as a sell. The area that we feel has been the company's primary weakness has been its feeble growth in its earnings per share. Get the full Acceleron Pharma Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null